A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 540 participants.
Also called NCT04557462
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 540 participants
- Sponsor
- Registry
-
NCT04557462 -
2020-002200-40
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Czechia, Denmark, France, Germany, Hong Kong SAR China, Hungary, India, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, Norway, Russia, Singapore, Slovakia, Slovenia, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand, Türkiye, United Kingdom, Vietnam
- Registry status
- Recruiting
Technical summary
Registry record NCT04557462. Allocation not applicable; no masking; primary purpose treatment. Start 2021-09-20 (actual); primary completion 2030-12-04 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- Condition
- Primary IgA Nephropathy
- Intervention (Drug)
- LNP023
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct04557462- Content hash
d58bd92a913c3d4e5645fbc8e3c560a72383465ab92b564086127343320bccd0